肝X受体
兴奋剂
炎症
脂肪变性
体内
药理学
化学
胆固醇逆向转运
受体
脂质代谢
胆固醇
内分泌学
内科学
医学
生物化学
核受体
生物
脂蛋白
生物技术
基因
转录因子
作者
Xue‐Qing Zhang,Orli Even‐Or,Xiaoyang Xu,Mariska G. M. van Rosmalen,Lucas Lim,Suresh Gadde,Omid Cameron Farokhzad,Edward A A Fisher
标识
DOI:10.1002/adhm.201400337
摘要
Liver X receptor (LXR) signaling pathways regulate lipid metabolism and inflammation, which has generated widespread interest in developing synthetic LXR agonists as potential therapeutics for the management of atherosclerosis. In this study, it is demonstrated that nanoparticles (NPs) containing the synthetic LXR agonist GW3965 (NP-LXR) exert anti-inflammatory effects and inhibit the development of atherosclerosis without causing hepatic steatosis. These NPs are engineered through self-assembly of a biodegradable diblock poly(lactide-co-glycolide)-b-poly(ethylene glycol) (PLGA-b-PEG) copolymer. NP-LXR is significantly more effective than free GW3965 at inducing LXR-target gene expression and suppressing inflammatory factors in macrophages in vitro and in vivo. Additionally, the NPs elicit negligible lipogenic gene stimulation in the liver. Using the Ldlr (-/-) mouse model of atherosclerosis, abundant colocalization of fluorescently labeled NPs within plaque macrophages following systemic administration is seen. Notably, six intravenous injections of NP-LXR over 2 weeks markedly reduce the CD68-positive cell (macrophage) content of plaques (by 50%) without increasing total cholesterol or triglycerides in the liver and plasma. Together, these findings identify GW3965-encapsulated PLGA-b-PEG NPs as a promising nanotherapeutic approach to combat atherosclerosis, providing the benefits of LXR agonists without their adverse effects on hepatic and plasma lipid metabolism.
科研通智能强力驱动
Strongly Powered by AbleSci AI